Vialwirebiotech, curated
October 1, 2026, 5:42 AM
August 26, 2026
- 4:46 AM · Pharmaceutical Technology4:46 AMMcKesson to acquire Precision Medicine Group for $2.25bn — Pharmaceutical Technology
- 4:00 AM · Drug Discovery World4:00 AMEC okays immunotherapy double regimen for multiple myeloma — Drug Discovery World
- 4:00 AM · Drug Discovery World4:00 AMWhen the world’s first solid-tumour CAR-T gets approved in China — Drug Discovery World
August 25, 2026
- 9:00 PM · SCMP — Tech9:00 PMChina rushes to develop Moderna-style cancer vaccines amid market frenzy — SCMP — Tech
- 12:00 PM · BioWorld12:00 PMDR3 next step in TL1A push? Shattuck, others busy — BioWorld
- 12:00 PM · BioWorld12:00 PMJazz-Actio $1B+ deal one of many efforts in epilepsy — BioWorld
- 12:00 PM · BioWorld12:00 PMFDA awards HDE approval to Oncosil device for bile duct cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMLundbeck halts TED study on eve of bexicaserin phase III readout — BioWorld
- 12:00 PM · BioWorld12:00 PM4-1BB revival? Leads’ bispecific for EP-NEC enters China review — BioWorld
- 12:00 PM · BioWorld12:00 PMHanmi that CV MoA: Roche lured to $2.3B metabolic pact — BioWorld
- 12:00 PM · BioWorld12:00 PMSolid tumor CAR T setback pushes Chimeric toward in vivo platform — BioWorld
- 9:43 AM · STAT News
- 9:22 AM · Pharmaceutical Executive9:22 AM<![CDATA[FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and Older]]> — Pharmaceutical Executive
- 9:20 AM · Drug Discovery World9:20 AMNew drug displays anti-inflammatory and neuroprotective effects in ALS — Drug Discovery World
- 9:00 AM · BioWorld9:00 AMVeraxa and Secarna make progress in conjugate collaboration — BioWorld
- 9:00 AM · BioWorld9:00 AMBiontech describes new antibody-drug conjugates — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMAstrazeneca discloses new HER2-targeting ADCs — BioWorld
- 9:00 AM · BioWorld9:00 AMKolm Therapeutics identifies new heterobifunctional compounds — BioWorld
- 9:00 AM · BioWorld9:00 AMOnkure Therapeutics patents new PI3K mutant inhibitors — BioWorld
- 8:00 AM · BioWorld8:00 AMRegulatory: NMPA approvals for Akeso, Geneseeq, Vcare — BioWorld
- 8:00 AM · BioWorld8:00 AMClinics: Phase III wins for Hutchmed, Taiho, Zai Lab and more — BioWorld
- 8:00 AM · BioWorld8:00 AMDeals/M&As: Iaso-Medisix acquisition; Tanabe dersimelagon deal — BioWorld
- 8:00 AM · BioWorld8:00 AMFinancings: Enginprime Medical closes series A — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMOrphan designation granted for Cushing’s syndrome mAb — Drug Discovery World
- 5:17 AM · Pharmaceutical Technology5:17 AMTakeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1 — Pharmaceutical Technology
- 1:00 AM · SCMP — Tech
August 24, 2026
- 12:00 PM · BioWorld12:00 PMRoche, Eli Lilly secure FDA clearance for Alzheimer’s blood-based test — BioWorld
- 12:00 PM · BioWorld12:00 PMRegenxbio’s Hunter syndrome gene therapy hits another snag — BioWorld
- 11:30 AM · BioPharma Dive11:30 AMFDA extends review of Capricor cell therapy; Pain drug startup to go public — BioPharma Dive
- 11:19 AM · BioPharma Dive11:19 AMCellares, a cell therapy manufacturing specialist, to lay off 100 employees — BioPharma Dive
- 9:47 AM · BioPharma Dive9:47 AMRoche commits to lean-mass preservation with Hanmi obesity deal — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMFDA clears Orum Therapeutics’ IND for ORM-1153 — BioWorld
- 6:00 AM · Drug Discovery World6:00 AMKynexis extends Series A to €97m to advance cognitive disorder drug — Drug Discovery World